Eli Lilly and Co Diabetes & Obesity Update at ADA Call Transcript
Ladies and gentlemen, thank you for standing by. Welcome to the ADA Investor Update. (Operator Instructions) As a reminder, today's conference is being recorded.
And I would now like to turn the conference over to our host, Lauren Zierke. Please go ahead.
Good morning. Thank you for joining us for Eli Lilly and Company's Obesity & Diabetes Update at ADA. I'm Lauren Zierke, Senior Director of Investor Relations. Joining me on today's call are Mike Mason, President of Lilly Diabetes; Dr. Dan Skovronsky, Chief Scientific and Medical Officer; Dr. Jeff Emmick, Vice President of Diabetes Product Development; Dr. Ruth Gimeno, Vice President of Diabetes Research and Clinical Investigation; and Jamie Croaning, Global Development Leader for Tirzepatide.
During this conference, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to several factors, including those listed on Slide 2. Additional
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |